Background {#Sec1}
==========

Prolonged pain from the musculoskeletal system and other symptoms currently associated with the diagnosis fibromyalgia have been described since ancient times \[[@CR1], [@CR2]\]. In the 1500s such symptoms was termed "rheumatism" \[[@CR3]\] and in the 1700s "muscular rheumatism" \[[@CR3]\]. From the early 1900s the term "psychogenic rheumatism" was presented, although it was assumed to be caused by muscular inflammation and preferentially named "fibrositis" \[[@CR4]--[@CR6]\]. Eventually, in 1976, the term fibromyalgia was coined \[[@CR7]\], as the symptoms were no longer considered to have an inflammatory cause, i.e. the past prevailing paradigm since Gowers in 1904 \[[@CR3], [@CR8]\]. The etiology and pathogenesis is since then often characterized as medically unexplained \[[@CR9]\]. However, fibromyalgia may be considered as a "discrete diagnosis or as a constellation of symptoms characterized by central nervous system pain amplification with concomitant fatigue, memory problems, and sleep and mood disturbances"\[[@CR10]\]. The estimated prevalence of fibromyalgia in the general population varies globally between approximately 2 and 11%, depending on the population and study design \[[@CR10], [@CR11]\]. The prevalence is higher in women than men (9:1), and increasing with age \[[@CR12]\]. The diagnosis has until recently been determined by clinical examination according to the ACR 1990 criteria, in which the patient must have pain in all of the body's four quadrants plus axial pain, and at least 11/18 predefined tender points, triggered by a pressure of a maximum of 4 kg/cm^2^ \[[@CR13]\]. In addition to being a chronic, widespread musculoskeletal pain condition without a well-defined cause, fibromyalgia is often accompanied by non-specific symptoms and comorbidities \[[@CR14]--[@CR16]\]. These include symptoms such as fatigue, memory and concentration problems \[[@CR17]\], sleep disturbances, stomach ache, depressive symptoms and headache \[[@CR10], [@CR18], [@CR19]\], and disorders like irritable bowel syndrome (IBS), chronic fatigue syndrome (CFS/ME), interstitial cystitis (IC) and temporomandibular disorder (TMD) \[[@CR8]\].

Due to the high prevalence of symptoms and comorbidities associated with fibromyalgia, researchers in various milieus have started to view fibromyalgia and related conditions as potentially explained by the same mechanisms \[[@CR20]\]. The prevailing view is that they represent a similar, altered central neural processing of perceptive stimuli, rather than organ-specific pathology. One suggested term to cover such a neural dysregulation condition is "centralized sensitization syndrome" (CSS) \[[@CR21], [@CR22]\]. Other research groups have launched concepts and theories, which are theoretically in good coherence with the notion of central sensitization. These include sustained arousal \[[@CR23]\], the Cognitive Activation Theory of Stress (CATS) \[[@CR24]\] and allostatic overload \[[@CR25]\]. Currently, these concepts exist more or less in parallel, and no consensus exists about the mechanisms \[[@CR26], [@CR27]\]. However, the diagnostic criteria for fibromyalgia have since 2010 been adapted to accommodate the frequent occurrence of associated symptoms and comorbidities \[[@CR18]\]. The diagnosis can now be established by therapist interviews and self-reports by summing the pain localizations (0--19) in a "widespread pain index" (WPI) plus adding a 0--12 ranged "symptom severity" score (SSS) considering the comorbid symptoms mentioned above. This completes the ACR 2010 fibromyalgia criteria and the later 2011 "Fibromyalgia survey criteria" by a sum score of maximum 31 points where the fibromyalgia diagnosis is defined by a 12 point cut-off score \[[@CR18], [@CR19]\].

Recently, researchers have taken interest in how patients with fibromyalgia experience hearing. One study has found increased incidence of reported subjective hearing loss among persons with fibromyalgia, compared to individuals with inflammatory rheumatic disorders \[[@CR28]\]. Fibromyalgia has also been associated with hypersensitivity to noise \[[@CR29]\]. These findings are interesting in light of the theories concerning central sensitization, and are compatible with studies of cognitive dysfunction and memory problems in fibromyalgia and chronic widespread pain \[[@CR17]\]. Another study has found poor correlations between subjective and objective hearing loss in patients with three or more medical unexplained symptoms, but that study did not include fibromyalgia per se \[[@CR30]\]. It is thereby still unclear whether persons with fibromyalgia are more likely to report hearing loss than others. According to the theory of sustained arousal, one might hypothesize that if persons with fibromyalgia can be shown to experience auditory disturbances in addition to the previously documented problems with cognitive function and memory \[[@CR17]\], similar auditory disturbances might also be found in persons with widespread muscular pain.

Based on The Nord-Trøndelag Health Study part 2 (HUNT2) and Nord-Trøndelag Hearing Loss study (NTHLS), the aim of the present study was to explore if people who report fibromyalgia or other musculoskeletal pain are more likely to have subjective hearing loss, compared to controls without such problems. More specifically, our research question is:

Are persons with fibromyalgia or other musculoskeletal pain, widespread or localized, more likely to report subjective hearing loss than persons without fibromyalgia or other pain, when adjusting for measured hearing thresholds, age, gender and education, as well as depression and anxiety?

Method {#Sec2}
======

Study design and participants {#Sec3}
-----------------------------

Data from HUNT 2 (1995--7) and the NTHLS were used in a retrospective cross-sectional study. HUNT2 and NTHLS are questionnaire-based, but hearing loss was assessed by audiologists who used mobile research units to measure audiometry.

In total, 66 140 adults, age ranging from 20 to 101 years participated in HUNT2. Median age was 48, and mean age 50.2 years \[[@CR31]\]. Hearing tests were available for 50 465 participants. Persons with missing data on fibromyalgia, musculoskeletal pain and subjective hearing loss were excluded from the present study (Fig. [1](#Fig1){ref-type="fig"}). All participants in HUNT 2 and NTHLS provided informed, written consent to participate in research studies.Fig. 1Inclusion form

Measures {#Sec4}
--------

### Fibromyalgia {#Sec5}

Fibromyalgia was assessed with the question: "Has a physician ever said that you have had fibromyalgia (fibrositis/chronic pain syndrome)?" (HUNT 2 Q1) \[[@CR32]\], with response alternatives "yes" or "no". An affirmative answer to this question classified respondents as having fibromyalgia. It is not known to what extent physicians used the tender-point criteria when establishing the diagnosis \[[@CR13]\].

### Other musculoskeletal pain {#Sec6}

Other musculoskeletal symptoms than fibromyalgia were evaluated by self-report questions from the HUNT2 Q1 questionnaire \[[@CR32]\]. Similar questions have shown good sensitivity and reproducibility in earlier studies \[[@CR33]--[@CR35]\]. The initial question was: "Have you during the past year suffered from pain and/or stiffness in muscles and limbs that have lasted for at least three consecutive months? If so, where did you have these ailments?" Subsequently the participant could select between 10 different localizations \[[@CR36]\]. Affirmative answers to one or more of the questions concerning musculoskeletal pain or stiffness, and not "yes" to the fibromyalgia question, were categorized as "having other musculoskeletal pain than fibromyalgia".

### Widespread or localized pain {#Sec7}

Persons with muscular and/or skeletal problems in three or more localizations were categorized as having "widespread musculoskeletal pain" \[[@CR37]\]. Those who had one to two localizations for musculoskeletal pain were categorized as having "localized musculoskeletal pain".

### Subjective hearing loss {#Sec8}

Subjective hearing loss (dependent variable) was assessed by the following questions and follow-up questions \[[@CR32]\]: "Do you have any long-term illness, injury or suffering of physical or psychological nature that impairs your functioning in your daily life?". Then, if yes, "Impaired hearing?" and "How much would you say that your functions are impaired?" with grading options 0--3 (0 = not impaired, 1 = slightly impaired, 2 = mediocrely impaired and 3 = seriously impaired). Options 1--3 were interpreted as subjective loss of hearing.

### Audiometry {#Sec9}

Audiometry measured the hearing threshold for air conduction. It was performed by trained personnel under good conditions \[[@CR31], [@CR38]\], and the method test-retest reliability is high \[[@CR39]\]. The audiometry was performed automatically with earmuffs connected to a PC. In cases where the participant was not able to conduct the test automatically, it was performed manually. Hearing thresholds were measured by increasing sound levels until there was a response from the person, and then the sound level was lowered by 10 dB and then increased by 5 dB, until a response was given once more \[[@CR39]\]. The frequencies 500, 1000, 2000 and 4000 Hz for both ears form the basis of a mean hearing threshold in this study. Hearing loss is defined by the World Health Organization (WHO) as a mean hearing threshold of 26 dB or higher \[[@CR40]\]. Mild hearing loss is mean hearing threshold of both ears between 26.0 dB and 40.9, moderate hearing loss is between 41.0 and 60.9 dB, and severe hearing loss is defined by mean hearing threshold of 61.0 dB or above \[[@CR41]\].

### Depression and anxiety symptoms {#Sec10}

Symptoms of depression and anxiety were assessed with the "Hospital Anxiety and Depression Scale" (HADS), a self-report form with seven questions for depressive symptoms (HADS-D) and seven questions for anxiety symptoms (HADS-A) with a score range from 0--21 points of each sub-scale. A score of ≥8 on each subscale indicates clinically relevant symptoms consistent with depression (HADS-D) or anxiety (HADS-A) \[[@CR42]\]. The HADS has been validated in Norway and found suitable for screening purposes \[[@CR43]\].

### Demographic and socioeconomic status {#Sec11}

Demographic variables were gender and age (whole years) and assessment of socioeconomic status included level of education (highest completed - from primary school to university) \[[@CR31]\].

Statistical analysis {#Sec12}
--------------------

Data was analyzed using SPSS version 22. Group differences of the participants were described by chi-square test for categorical variables and two-sided *t*-test for continuous variables.

Unadjusted and adjusted logistic regression analyses (the Enter method, i.e. including all relevant variables simultaneously) were used to assess the main outcome of the study (to have subjective loss of hearing vs. no loss of hearing) of participants in HUNT2 with fibromyalgia versus the reference group. In addition, participants with other, widespread and localized, musculoskeletal pain were compared with the reference group. The reference group was participants without musculoskeletal pain. Men and women were analyzed separately. We adjusted for previously known confounding factors for subjective loss of hearing: measured loss of hearing (thresholds), socio-demographic factors (age and education), and psychological distress (clinical symptoms of depression and anxiety). Measured loss of hearing and age were not linearly associated with the outcome in any of the subgroups and was categorized. Two adjusted models were presented for both comparisons. Model 1 adjusted for age, education, and measured hearing thresholds. Model 2 was additionally adjusted for clinical symptoms of anxiety and depression.

Probability values less than 0.05 were considered statistically significant.

Results {#Sec13}
=======

Descriptive account of participants {#Sec14}
-----------------------------------

The prevalence of fibromyalgia among participants who answered these questions in HUNT 2 and underwent audiometry testing was 3.3% (*N* = 1 483). The prevalence for other musculoskeletal pain was for local pain 19.7% (*N* = 8 749), for widespread pain 22.6% (*N* = 10 059), and for local and widespread pain combined 42.3% (*N* = 18 808). Respondents who had fibromyalgia or other musculoskeletal pain were more often women, in a relationship, older, with lower level of education, higher scores of anxiety and depressive symptoms and higher average hearing thresholds than the reference group without fibromyalgia and musculoskeletal pain (Table [1](#Tab1){ref-type="table"}).Table 1Descriptive statisticsFibromyalgia (FM)Musculoskeletal pain without fibromyalgia (MS)ReferenceComparison (*P*-value)^a^FM vs RefMS vs RefTotal*N* (%)1 483 (100)18 808 (100)24 203 (100)Women*N* (%)1 275 (85.97)9 948 (52.89)11 860 (49.00)0.0000.000AgeMean (SD)52.43 (12.02)51.64 (15.56)45.99 (16.77)0.0000.000Single*N* (%)453 (30.55)6 340 (33.71)10 319 (42.63)0.0000.000Education0.0000.000 Primary school*N* (%)716 (48.28)7 042 (37.44)6 647 (27.46) High school*N* (%)552 (37.22)7 936 (42.19)11 091 (45.82) Higher*N* (%)215 (14.50)3 830 (20.36)6 465 (26.71)Audiometry (MTH)Mean (SD)16.82 (13.19)17.65 (14.80)14.29 (13.86)0.0000.000HADS-A^b^Mean (SD)6.38 (4.16)4.63 (3.43)3.57 (2.86)0.0000.000HADS-D^b^Mean (SD)5.07 (3.65)3.83 (3.15)2.81 (2.67)0.0000.000Reference = Ref = participants without fibromyalgia and musculoskeletal pain disordersMTH = mean threshold of hearing based on pure tone audiometry at frequencies 0.5, 1, 2 and 4 kHz on both earsHADS-A = self-reported questionnaire for symptoms of anxietyHADS-D = self-reported questionnaire for symptoms of depression^a^Descriptive comparison of categorical variables performed with chi-square and continuous variables with two-sided *t*-test^b^Missing data from several participants on this variable. Applicable for FM, MSD and Ref

Table [2](#Tab2){ref-type="table"} describes the two subgroups of persons with local and widespread musculoskeletal pain other than fibromyalgia. Persons with widespread pain were more commonly women, in a relationship, older, with lower level of education and higher scores of anxious and depressive symptoms, compared to persons with local musculoskeletal pain.Table 2Local vs widespread musculoskeletal pain disorders without fibromyalgiaLocal musculoskeletal pain (LMS)Widespread musculoskeletal pain (WMS)Comparison LMS vs WMS (*P*-value)^a^Total*N* (%)8 749 (100)10 059 (100)Women*N* (%)4 158 (47.52)5 790 (57.56)0.000AgeMean (SD)50.65 (16.21)52.50 (14.91)0.000Single*N* (%)3 067 (35.06)3 273 (32.54)0.000Education0.000 Primary school*N* (%)2 937 (33.57)4 105 (40.81) High school*N* (%)3 805 (43.49)4 131 (41.07) Higher*N* (%)2 007 (22.94)1 823 (18.12)Audiometry (MTH)Mean (SD)17.26 (14.81)18.00 (14.78)0.001HADS-A^b^Mean (SD)4.13 (3.11)5.07 (3.63)0.000HADS-D^b^Mean (SD)3.48 (2.97)4.14 (3.27)0.000MTH = mean threshold of hearing based on pure tone audiometry at frequencies 0.5, 1, 2 and 4 kHz on both earsHADS-A = self-reported questionnaire for symptoms of anxietyHADS-D = self-reported questionnaire for symptoms of depression^a^Descriptive comparison of categorical variables performed with chi-square and continuous variables with two-sided *t*-test^b^Missing data from several participants on this variable. Applicable for FM, MSD and Ref

The relationship between fibromyalgia and subjective hearing loss {#Sec15}
-----------------------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows that persons with fibromyalgia had increased probability of reporting subjective hearing loss, compared to persons in the reference group. The OR (95% CI) for subjective hearing loss was 5.182 (4.278--6.277) for women and 4.368 (3.082--6.189) for men with fibromyalgia, compared to women and men in the reference group after adjustment for age, education and measured hearing thresholds (WHO grade) (model 1). After additional adjustment for clinically relevant anxious and depressive symptoms (HADS-A ≥ 8 and HADS-D ≥ 8) (model 2), the OR (95% CI) for subjective hearing loss was 4.578 (3.622--5.787) for women and 4.523 (3.077--6.647) for men with fibromyalgia.Table 3OR (95 % CI) for subjective hearing loss by fibromyalgia, socioeconomic conditions, measured hearing loss, depression and anxiety in women and men^a^Subjective hearing lossUnadjustedAdjusted for age, education and hearing loss (model 1)In addition adjusted for anxiety and depression (model 2)YesNo*N* (%)*N* (%)OR (95% CI)OR (95% CI)OR (95% CI)WOMEN (13 135)1 085 (8.26)12 050 (91.74)Fibromyalgia No805 (6.79)11 055 (93.21)1.000 ref1.000 ref1.000 ref Yes280 (21.96)995 (78.04)3.865 (3.324--4.493)5.182 (4.278--6.277)4.578 (3.622--5.787)Age 20--3589 (2.09)4 162 (97.91)1.000 ref1.000 ref1.000 ref 36--49135 (3.36)3 881 (96.64)1.627 (1.240--2.133)1.069 (0.801--1.426)0.974 (0.713--1.329) 50--64279 (10.24)2 445 (89.76)5.336 (4.182--6.809)2.072 (1.565--2.743)1.952 (1.437--2.651) 65+582 (27.15)1 562 (72.85)17.424 (13.837--21.942)2.354 (1.747--3.172)2.071 (1.474--2.909)Education Primary school659 (15.45)3 606 (84.55)1.000 ref1.000 ref1.000 ref High school247 (4.49)5 255 (95.51)0.257 (0.221--0.299)0.807 (0.665--0.980)0.736 (0.588--0.921) Higher179 (5.15)3 189 (94.69)0.307 (0.259--0.365)0.811 (0.658--1.000)0.799 (0.618--1.032)WHO hearing impairment None (\<26 dB)377 (3.31)11 007 (96.69)1.000 ref1.000 ref1.000 ref Mild (26--40 dB)325 (28.33)822 (71.67)11.544 (9.793--13.606)7.859 (6.404--9.644)8.082 (6.340--10.302) Moderate (41--60 dB)291 (59.75)196 (40.25)43.348 (35.201--53.380)31.533 (24.444--40.678)35.904 (26.424--48.786) Severe (\>60 dB)92 (78.63)25 (21.37)107.442 (68.247--169.148)81.067 (50.190--130.939)90.053 (49.378--164.234)HADS--A ≥8^b^ No606 (6.11)9 312 (93.89)1.000 ref1.000 ref Yes178 (11.83)1 327 (88.17)2.061 (1.727--2.460)1.732 (1.353--2.217)HADS-D ≥8^b^ No786 (6.91)10 590 (93.09)1.000 ref1.000 ref Yes155 (17.44)734 (82.56)2.845 (2.358--3.433)1.131 (0.849--1.508)Nagelkerke R^2^0.3890.375−2 Log likelihood5 056.2653 744.466MEN (12 551)1 404 (11.19)11 147 (88.81)Fibromyalgia No1 335 (10.82)11 008 (89.18)1.000 ref1.000 ref1.000 ref Yes69 (33.17)139 (66.83)4.093 (3.050--5.493)4.368 (3.082--6.189)4.523 (3.077--6.647)Age 20--35150 (3.93)3 666 (96.07)1.000 ref1.000 ref1.000 ref 36--49173 (4.54)3 638 (95.46)1.162 (0.930--1.453)1.007 (0.800--1.268)0.966 (0.757--1.233) 50--64332 (12.40)2 346 (87.60)3.459 (2.833--4.223)1.692 (1.351--2.119)1.609 (1.262--2.050) 65+749 (33.35)1 497 (66.65)12.228 (10.159--14.718)2.116 (1.661--2.695)1.837 (1.404--2.403)Education Primary school611 (19.72)2 487 (80.28)1.000 ref1.000 ref1.000 ref High school505 (8.22)5 636 (91.78)0.365 (0.321--0.414)0.914 (0.783--1.066)0.886 (0.757--1.233) Higher288 (8.70)3 024 (91.30)0.388 (0.334--0.450)0.824 (0.691--0.981)0.765 (0.622--0.940)WHO hearing impairment None (\<26 dB)438 (4.36)9 618 (95.64)1.000 ref1.000 ref1.000 ref Mild (26--40 dB)439 (28.16)1 120 (71.84)8.607 (7.437--9.961)5.625 (4.713--6.715)6.157 (5.054--7.500) Moderate (41--60 dB)410 (53.39)358 (46.61)25.148 (21.194--29.841)15.120 (12.203--18.734)17.012 (13.214--21.902) Severe (\>60 dB)117 (69.64)51 (30.36)50.376 (35.766--70.955)31.310 (21.721--45.133)29.566 (19.085--45.802)HADS-A ≥8^b^ No949 (9.20)9 368 (90.80)1.000 ref1.000 ref Yes128 (13.43)825 (86.57)1.532 (1.257--1.867)1.583 (1.225--2.044)HADS-D ≥8^b^ No1 040 (9.49)9 915 (90.51)1.000 ref1.000 ref Yes183 (21.79)657 (78.21)2.655 (2.227--3.166)1.429 (1.118--1.826)Nagelkerke R^2^0.3190.296−2 Log likelihood6 593.2525 200.042HADS-A = self-reported questionnaire for symptoms of anxiety in which a score of ≥8 is consistent with clinically relevant symptoms of anxietyHADS-D = self-reported questionnaire for symptoms of depression in which a score of ≥8 is consistent with clinically relevant symptoms of depression^a^N in this analysis ranges from 13 135 to 11 113 and 12 551 to 10 961 for respectively women and men^b^Missing data from several participants on this variable

The relationship between other musculoskeletal pain than fibromyalgia and subjective hearing loss {#Sec16}
-------------------------------------------------------------------------------------------------

Table [4](#Tab4){ref-type="table"} shows that non-fibromyalgic persons who had local and widespread musculoskeletal pain had increased probability of subjective hearing loss, compared to the reference group. The probability was stronger in the subgroup with widespread musculoskeletal pain, compared to the subgroup with localized pain. The OR (95% CI) for subjective hearing loss was 1.901 (1.657--2.182) for women and 1.851 (1.662--2.061) for men with local musculoskeletal pain, and 3.145 (2.788--3.548) for women and 3.739 (3.375--4.142) for men with widespread musculoskeletal pain, compared to the reference group after adjustment for age, education and measured hearing thresholds (model 1). After additional adjustment for clinically relevant anxious and depressive symptoms (model 2), the OR (95% CI) for subjective hearing loss was 1.915 (1.627--2.255) for women and 1.796 (1.590--2.029) for men with local musculoskeletal pain, and 3.073 (2.668--3.539) for women and 3.618 (3.225--4.058) for men with widespread musculoskeletal pain.Table 4OR (95 % CI) for subjective hearing loss by musculoskeletal pain, socioeconomic conditions, measured hearing loss, depression and anxiety in women and men^a^Subjective hearing lossUnadjustedAdjusted for age, education and hearing loss (model 1)In addition adjusted for anxiety and depression (model 2)YesNo*N* (%)*N* (%)OR (95% CI)OR (95% CI)OR (95% CI)WOMEN (21 808)2 383 (10.93)19 425 (89.07)Musculoskeletal pain None805 (6.79)11 055 (93.21)1.000 ref1.000 ref1.000 ref Local558 (13.42)3 600 (86.58)2.129 (1.899--2.386)1.901 (1.657--2.182)1.915 (1.627--2.255) Widespread1 020 (17.62)4 770 (82.38)2.937 (2.661--3.240)3.145 (2.788--3.548)3.073 (2.668--3.539)Age 20--35156 (2.61)5 829 (97.39)1.000 ref1.000 ref1.000 ref 36--49283 (4.22)6 426 (95.78)1.646 (1.349--2.007)1.212 (0.987--1.490)1.172 (0.940--1.460) 50--64552 (11.21)4 371 (88.79)4.719 (3.934--5.661)2.202 (1.800--2.693)2.220 (1.785--2.762) 65+1 392 (33.21)2 799 (66.79)18.583 (15.654--22.059)2.916 (2.357--3.608)3.064 (2.415--3.887)Education Primary school1 470 (19.31)6 143 (80.69)1.000 ref1.000 ref1.000 ref High school505 (5.68)8 387 (94.32)0.252 (0.226--0.280)0.761 (0..665--0.870)0.771 (0.661--0.899) Higher408 (7.69)4 895 (92.31)0.348 (0.310--0.391)0.836 (0.726--0.964)0.896 (0.756--1.061)WHO hearing impairment None (\<26 dB)835 (4.52)17 619 (95.48)1.000 ref1.000 ref1.000 ref Mild (26--40 dB)723 (33.32)1 447 (66.68)10.543 (9.419--11.805)6.150 (5.367--7.047)6.393 (5.445--7.506) Moderate (41--60 dB)644 (67.08)316 (32.92)43.002 (36.959--50.035)25.229 (21.099--30.168)25.202 (20.300--31.286) Severe (\>60 dB)181 (80.80)43 (19.20)88.819 (63.239--124.745)57.021 (39.859--81.574)53.218 (34.360--82.427)HADS-A ≥8^b^ No1 365 (8.61)14 493 (91.39)1.000 ref1.000 ref Yes405 (14.06)2 476 (85.94)1.737 (1.542--1.956)1.703 (1.448--2.004)HADS-D ≥8^b^ No1 707 (9.21)16 830 (90.79)1.000 ref1.000 ref Yes361 (20.74)1 379 (79.25)2.581 (2.275--2.928)1.285 (1.063--1.552)Nagelkerke R^2^0.3900.378−2 Log likelihood10 334.6337 789.274MEN (21 203)3 576 (16.87)17 627 (83.13)Musculoskeletal pain None1 335 (10.82)11 008 (89.18)1.000 ref1.000 ref1.000 ref Local884 (19.26)3 707 (80.74)1.966 (1.792--2.158)1.851 (1.662--2.061)1.796 (1.590--2.029) Widespread1 357 (31.79)2 912 (68.21)3.843 (3.526--4.187)3.739 (3.375--4.142)3.618 (3.225--4.058)Age 20--35263 (5.07)4 926 (94.93)1.000 ref1.000 ref1.000 ref 36--49489 (7.60)5 946 (92.40)1.540 (1.320--1.798)1.124 (0.957--1.321)1.064 (0.898--1.261) 50--641 076 (19.97)4 311 (80.03)4.675 (4.061--5.382)1.978 (1.692--2.321)1.934 (1.638--2.284) 65+1 758 (41.70)2 444 (58.30)13.396 (11.665--15.385)2.375 (2.001--2.818)2.152 (1.784--2.597)Education Primary school1 658 (27.29)4 418 (72.71)1.000 ref1.000 ref1.000 ref High school1 313 (12.96)8 822 (87.04)0.397 (0.366--0.430)0.892 (0.808--0.985)0.884 (0.791--0.988) Higher605 (12.12)4 387 (87.88)0.367 (0.332--0.407)0.757 (0.671--0.854)0.688 (0.598--0.791)WHO hearing impairment None (\<26 dB)1 222 (7.50)15 080 (92.50)1.000 ref1.000 ref1.000 ref Mild (26--40 dB)1 135 (37.36)1 903 (62.64)7.360 (6.701--8.084)4.775 (4.270--5.341)4.842 (4.361--5.600) Moderate (41--60 dB)962 (62.63)574 (37.37)20.682 (18.368--23.288)12.982 (11.221--15.020)13.428 (11.428--16.060) Severe (\>60 dB)257 (78.59)70 (21.41)45.307 (34.566--59.386)31.241 (23.419--41.677)29.054 (20.611--40.956)HADS-A ≥8^b^ No2 386 (14.25)14 352 (85.75)1.000 ref1.000 ref Yes448 (21.13)1 672 (78.87)1.612 (1.440--1.804)1.443 (1.242--1.676)HADS-D ≥8^b^ No2 577 (14.39)1 533 (85.61)1.000 ref1.000 ref Yes585 (30.02)1 364 (69.98)2.552 (2.296--2.836)1.555 (1.342--1.801)Nagelkerke R^2^0.3610.348−2 Log likelihood14 108.01411 358.869HADS-A = self-reported questionnaire for symptoms of anxiety in which a score of ≥8 is consistent with clinically relevant symptoms of anxietyHADS-D = self-reported questionnaire for symptoms of depression in which a score of ≥8 is consistent with clinically relevant symptoms of depression^a^ *N* in this analysis ranges from 21 808 to 18 210 and 21 203 to 18 355 for respectively women and men^b^Missing data from several participants on this variable

Discussion {#Sec17}
==========

In this population-based study, we found that both persons who had been diagnosed with fibromyalgia and persons with other musculoskeletal pain had increased probability for subjective hearing, compared with a reference group without fibromyalgia or other musculoskeletal pain. The findings were adjusted for gender, age, education, measured hearing impairment (audiometry, WHO graded), clinical relevant symptoms indicating anxiety and/or depression. Non-fibromyalgia respondents with widespread musculoskeletal pain had significantly higher odds to report subjective hearing loss than persons with only localized pain.

Main findings in light of theories about central nervous sensitization {#Sec18}
----------------------------------------------------------------------

The previously mentioned theories about sustained arousal, CATS and allostatic overload all conceptualize how prolonged stress, probably in association with a genetic predisposition \[[@CR44]\], lead to sensitization of the central nervous system, thereby enhancing the sensitivity to stimuli, by some researchers termed central sensitization syndrome (CSS) \[[@CR24], [@CR25]\]. This indicates that both fibromyalgia and other musculoskeletal pain might to a certain extent be explained by altered central pain processing. Central mechanisms might explain both subjective alterations in the experience of auditory stimuli and cognitive dysfunction \[[@CR17]\]. In future studies, it would be interesting to address auditory perception among patients with fibromyalgia and other chronic pain in a prospective and nuanced manner, encompassing both experiences of explicit hearing problems and hypersensitivity to sound.

Comparisons with previous studies {#Sec19}
---------------------------------

To our knowledge, our study is the first to report a relationship between subjective hearing loss and fibromyalgia, as well as for other musculoskeletal pain in a general population. The findings are in line with the previously mentioned clinical study by Wolfe et al. \[[@CR28]\], which however did not adjust for audiometrically measured hearing loss. Hashimoto et al. \[[@CR30]\] who revealed similar findings for conditions with three or more medical unexplained symptoms did not include fibromyalgia or other musculoskeletal pain disorders, nor did they adjust for depression and anxiety symptoms, but adjusted for measured hearing loss.

Strengths and limitations {#Sec20}
-------------------------

This study has several strengths. Firstly, despite the large sample size (over 40 000 participants) and the self-report approach used in the study, all participants were assessed with audiometry in both ears with a validated procedure. Thus, it was possible to adjust the analysis of subjective hearing loss with objectively measured hearing thresholds. Furthermore, the large sample size gave power to run subgroup analyses and adjust for a number of conditions known to affect subjective health and hearing \[[@CR28], [@CR45], [@CR46]\].

Moreover, it is a strength that fibromyalgia and other musculoskeletal pain were studied separately in this study. This is because the new diagnostic criteria for fibromyalgia include more than just widespread musculoskeletal pain \[[@CR18], [@CR19]\]. They also include cognitive dysfunction/problems, as stated in the introduction \[[@CR17], [@CR19]\].

Questions concerning musculoskeletal pain have been validated through several studies \[[@CR33], [@CR34]\] where they compared the answers on the questionnaires against the diagnoses cervical spondylosis, adhesive capsulitis, lateral epicondylitis, carpal tunnel syndrome and Raynaud's phenomenon \[[@CR33]\]. Thus, the pain questions and pain map used in HUNT 2, i.e. the Nordic pain questionnaire (NPQ), appear relevant and valid \[[@CR34]\].

The study also has some limitations. Firstly, the participants were not diagnosed by physicians in the study setting. The fibromyalgia diagnosis thus relied on the participant's response to whether a physician prior in time had said the person had fibromyalgia. Thus, we do not know if the persons responding "yes" to fibromyalgia was evaluated using the formal diagnostic criteria. The HUNT study was conducted in 1995--1997 when the 1990 diagnostic criteria for fibromyalgia were in force, thus 2010 criteria were not used. Furthermore, we cannot rule out the possibility that participants who reported widespread pain had undiagnosed fibromyalgia. In addition, we cannot exclude that wording in the questions concerning reported subjective hearing loss influenced the responses. Furthermore, since this is a retrospective cross-sectional study, conclusions concerning causality cannot be drawn from the results.

Conclusions {#Sec21}
===========

Our study showed increased probability for subjective hearing loss, both in persons with fibromyalgia and other musculoskeletal pain, especially widespread pain, after adjustment of audiometric measured hearing loss and sociodemographic and psychological variables. The finding supports the increasing recognition that medically unexplained pain conditions may pertain to a larger spectrum of symptoms, and that a common denominator for the different symptoms might be a more general dysregulation in perception of sensory stimuli.
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